218 related articles for article (PubMed ID: 26882440)
1. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H
Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440
[TBL] [Abstract][Full Text] [Related]
2. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
3. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells.
Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S
Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417
[TBL] [Abstract][Full Text] [Related]
4. Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.
Kakehashi A; Stefanov VE; Ishii N; Okuno T; Fujii H; Kawai K; Kawada N; Wanibuchi H
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218651
[TBL] [Abstract][Full Text] [Related]
5. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
[TBL] [Abstract][Full Text] [Related]
7. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma.
Maki A; Kono H; Gupta M; Asakawa M; Suzuki T; Matsuda M; Fujii H; Rusyn I
Ann Surg Oncol; 2007 Mar; 14(3):1182-90. PubMed ID: 17195915
[TBL] [Abstract][Full Text] [Related]
8. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
9. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.
Shirasaki T; Honda M; Yamashita T; Nio K; Shimakami T; Shimizu R; Nakasyo S; Murai K; Shirasaki N; Okada H; Sakai Y; Sato T; Suzuki T; Yoshioka K; Kaneko S
Sci Rep; 2018 Sep; 8(1):13143. PubMed ID: 30177680
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.
Ali N; Allam H; May R; Sureban SM; Bronze MS; Bader T; Umar S; Anant S; Houchen CW
J Virol; 2011 Dec; 85(23):12292-303. PubMed ID: 21937640
[TBL] [Abstract][Full Text] [Related]
12. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.
Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874
[TBL] [Abstract][Full Text] [Related]
13. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori-Infected CAPZA1-Overexpressing Cells.
Tsugawa H; Kato C; Mori H; Matsuzaki J; Kameyama K; Saya H; Hatakeyama M; Suematsu M; Suzuki H
Cell Mol Gastroenterol Hepatol; 2019; 8(3):319-334. PubMed ID: 31146068
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.
Chen J; Yu Y; Ji T; Ma R; Chen M; Li G; Li F; Ding Q; Kang Q; Huang D; Liang X; Lin H; Cai X
Cancer Med; 2016 Oct; 5(10):2678-2687. PubMed ID: 27650414
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
16. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
17. Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling.
Sun L; Beggs K; Borude P; Edwards G; Bhushan B; Walesky C; Roy N; Manley MW; Gunewardena S; O'Neil M; Li H; Apte U
Am J Physiol Gastrointest Liver Physiol; 2016 Jul; 311(1):G91-G104. PubMed ID: 27151938
[TBL] [Abstract][Full Text] [Related]
18. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.
Hsu HC; Jeng YM; Mao TL; Chu JS; Lai PL; Peng SY
Am J Pathol; 2000 Sep; 157(3):763-70. PubMed ID: 10980116
[TBL] [Abstract][Full Text] [Related]
19. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T
Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation.
Mizuochi S; Akiba J; Kondo R; Kusano H; Shioga T; Kondo K; Tsutsui K; Nakayama M; Ogasawara S; Naito Y; Nakashima O; Yano H
Anticancer Res; 2022 Jan; 42(1):449-457. PubMed ID: 34969755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
